The exact pathophysiology of microscopic colitis is not completely understood, though PPIs and NSAIDs are 2 medications commonly implicated for triggering the inflammatory process.
Current research indicates that short-term utilization of an LFD may help ameliorate some mild IBS symptoms associated with quiescent IBD, while further long term studies are still needed.
In patients with IBD, management of immunosuppressive regimens, as well as safety and efficacy of vaccines, has raised many questions during the COVID-19 pandemic.
Though patient use of cannabinoids for the treatment of IBD has increased, clinical decision making on whether to formally recommend it as treatment remains difficult.
The decision whether or not to treat patients with portal vein thrombosis is frequently encountered and remains a challenge.
Initiation of opioid use during a flare of symptoms can eventually lead to chronic opioid use (COU), which can have detrimental effects on a patient’s IBD, as well as their overall clinical health.
The authors review gut dysfunction and microbiota changes during HIV infection and IBD and discuss how they may induce a dysfunctional mucosal barrier, dysbiosis, and changes on the cellular level, including monocytes, macrophages, and dendritic cells.
C. Andrew Kistler, MD, PharmD, examines existing data about bariatric surgery and the risk for subsequent colorectal cancer development.
A clinician discusses whether inflammatory bowel disease is a risk factor for the development of dementia.
Vitamin D is a biomarker of interest in the pancreatic cancer setting.
